Frendsworth, Texas, USA, November 11, 2026 / PRNewswire / -- Castle Biosciences, Inc. (Nasdaq ticker: CSTL) Today, the company announced that its executive team plans to provide a company overview at the 38th Annual Healthcare Conference on Piper Sandler on Wednesday, December 2, 2026, at 8:10 a.m. Eastern Time.
The live audio broadcast of the company's speech can be listened to by visiting the website Castle Biosciences at ir.castlebiosciences.com / events-presentations. A replay will be provided after the live broadcast ends.
About Castle Biosciences
Castle Biosciences (Nasdaq ticker: CSTL) is a leading diagnostics company that improves health outcomes through innovative tests that provide guidance for patient care decisions. The company focuses primarily on dermatology and gastrointestinal diseases, developing personalized and clinically actionable solutions to help improve disease management and patient outcomes.
The company states that it always puts people first – empowering patients and clinicians through rigorous science and advanced molecular testing, and providing support for more confident treatment planning. For more information, please visit www.CastleBiosciences.com, and follow the company on LinkedIn, Instagram, Facebook, and X.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMSeq are all trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero[ email protected ]Media contact:
Allison Marshall[ email protected ]
